Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Emma Guttman-Yassky
Icahn School of Medicine at Mount Sinai, New York, USA

Stephan Weidinger
University Hospital Schleswig-Holstein, Kiel, Germany

Eric Simpson
Oregon Health & Science University, Portland, USA

Melinda Gooderham
SKiN for Dermatology, Probity Medical Research and Queen’s University, Peterborough, Canada

Alan Irvine
Children’s Health Ireland, Dublin, Ireland

Lynda Spelman
Veracity Clinical Research, Brisbane, Australia, and Probity Medical Research, Woolloongabba, Queensland, Australia

Jonathan Silverberg
George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Hany Elmaraghy
Eli Lilly and Company, Indianapolis, USA

Louise DeLuca-Carter
Eli Lilly and Company, Indianapolis, USA

Maria Lucia Buziqui Piruzeli
Eli Lilly and Company, Indianapolis, USA

Chaoran Hu
Eli Lilly and Company, Indianapolis, USA

Fan Emily Yang
Eli Lilly and Company, Indianapolis, USA

Evangeline Pierce
Eli Lilly and Company, Indianapolis, USA

Laia Bardolet
Almirall S.A, Barcelona, Spain

Diamant Thaci
Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany

Keywords

Lebrikuzumab, atopic dermatitis, efficacy, safety

References

1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

2. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

3. Simpson E, et al. JAMA Dermatol. 2023;159:182-191.

4. Blauvelt et al. Br J Dermatol. 2023;188:740-748

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.271

Article Details

How to Cite
[1]
Guttman-Yassky, E. , Weidinger, S. , Simpson, E. , Gooderham, M. , Irvine, A. , Spelman, L. , Silverberg, J. , Elmaraghy, H. , DeLuca-Carter, L. , Buziqui Piruzeli, M.L. , Hu, C. , Yang, F.E. , Pierce, E. , Bardolet, L. and Thaci, D. 2023. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s271. DOI:https://doi.org/10.25251/skin.7.supp.271.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 11 12 13 14 15 16 17 > >>